Patient P-01879
Therapy response
Improving
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
93%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 No meaningful change — Dietary Support Protocol NP-02
- Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 46 SC-12 recommended — Supportive Compound SC-12
- Day 47 Patient accepted — Started SC-12 in the companion
- Day 53 GI symptom burden −16% vs expected — Supportive Compound SC-12
- Day 59 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 46.
Primary contributors, last 14 days
- GI instability+7
- Toxicity-5
What helped?
- Dietary Support Protocol NP-02Day 31Result: no meaningful change
- Supportive Compound SC-12Day 46Result: symptom burden −16%
LIFE OS recommendation
GI Support Protocol GI-04
87%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑95
- DNACYP2D6 poor metabolizer → higher exposure
- DNADPYD *2A → slower clearance
- BloodToxicity index 46
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑65
- WearableResting HR 86 bpm
- Wearable395 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 51 and rising
- Inflammatory signalling ↓40
- BloodInflammatory load index 49
- WearableHRV 19 ms, trending down
DNA
Fictional pharmacogenomic panel
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 1.8 · butyrate capacity 40/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 17 ms
- Sleep
- 6.3 h
- Steps
- 1,172
- Resting HR
- 85 bpm
Daily log: GI score 51, nutritional resilience 44, adherence 47.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01804 | 22% | S19 | AD-05 | improved | 61 |
| P-01696 | 32% | S20 | CR-01 | improved | 59 |
| P-01708 | 32% | S07 | CR-01 | improved | 59 |
| P-01371 | 31% | S06 | CR-01 | improved | 63 |
| P-01835 | 31% | S17 | CR-01 | improved | 56 |
| P-01388 | 30% | S17 | CR-01 | improved | 59 |
| P-01442 | 29% | S13 | CR-01 | improved | 61 |
| P-01877 | 28% | S01 | CR-01 | improved | 67 |
| P-01430 | 23% | S05 | CR-01 | improved | 54 |
| P-01767 | 22% | S14 | DT-01 | no change | 63 |
| P-01342 | 21% | S11 | DT-01 | improved | 48 |
| P-01346 | 21% | S12 | DT-01 | improved | 52 |